benzoxazoles has been researched along with Angiogenesis, Pathologic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y; Hu, T; Li, K; Li, Z; Song, J; Tang, L | 1 |
| Akita, S; Fujitaka, K; Haruta, Y; Hattori, N; Ishikawa, N; Kohno, N; Masuda, T; Murai, H; Senoo, T | 1 |
| Akita, S; Fujitaka, K; Hamada, H; Hattori, N; Iwamoto, H; Kohno, N; Masuda, T; Omori, K; Takayama, Y | 1 |
| Badve, S; Gökmen-Polar, Y; Liu, Y; Mehta, R; Rommel, C; Sanders, KL; Sledge, GW; Toroni, RA | 1 |
4 other study(ies) available for benzoxazoles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
mTOR inhibition by TAK-228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Tumor; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Pyrimidines; Retinal Neoplasms; Retinoblastoma; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2022 |
SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Benzoxazoles; Carcinoma, Lewis Lung; Cell Line, Tumor; Dicarboxylic Acids; Disease Progression; Gene Knockdown Techniques; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Plasminogen Activator Inhibitor 1 | 2013 |
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Biomarkers, Tumor; Blotting, Western; Cell Movement; Cell Proliferation; Cisplatin; Dicarboxylic Acids; Drug Therapy, Combination; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Neovascularization, Pathologic; Plasminogen Activator Inhibitor 1; Pleural Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Topics: Animals; Antineoplastic Agents; Benzoxazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Endothelial Cells; Female; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Multiprotein Complexes; Mutation; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |